OBJECTIVES

Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T), seen as a game-changing technology, has become a new wave. Based on the characteristics and hot spots of global pharmaceutical technology innovation, this research explores the CAR-T patent layout and drug development trends to analyze the CAR-T technology competitive landscape, market prospects, prevalent trends as well as sharing value in this domain.

METHODS

Patent information and clinical data related to CAR-T were retrieved from the Derwent Innovation and Clinical Trials up to 2019, on the basis of RIPL statement and PRISMA.

RESULTS

Through a series of manual reviews, 11290 patent documents and 631 clinical registrations were extracted. (1) Patent landscape:The United States is still the most productive country, with 3116 patents applied, followed by China with 1,794. The University of Pennsylvania holds 848 CAR-T patents and is an undisputed leader, including 411 patents generated through cooperation with Novartis. (2) Clinical research:A total of 319 CAR-T projects in China are in clinical trials, surpassing 218 in the United States. There are more than 100 cooperations between enterprises, schools and hospitals, with up to 99 R & D cooperations between schools and enterprises. (3) Market prospects:CAR-T therapy has shown immense technological progress in the areas of personalized medicine and rare disease, which will become a new investment hotspot, and China will become the center of international capital competition.

CONCLUSIONS

With the development of innovation driven economy, the competition among enterprises will be increasingly fierce in the future.To avoid risks more appropriately, downstream enterprises will strengthen the search for core technologies in universities or research institutions. Public and private sectors began to integrate resources, jointly develop universal CAR-T technology, and form an open innovation model based on cooperative innovation.In terms of the overall environment, CAR-T will definitely accelerate the commercialization process under the impetus of demand, technology, capital and policy.